Boston Scientific Corp. has agreed to acquire medical device manufacturer Baylis Medical Company Inc. for $1.75 billion, subject to closing adjustments. The acquisition will expand the Boston Scientific electrophysiology and structural heart product portfolios to include the radiofrequency (RF) NRG and VersaCross Transseptal Platforms as well as a family of guidewires, sheaths, and dilators used to support left heart access.

These platforms have transseptal puncture that the developers say increase efficiency when crossing the atrial septum to deliver therapies in the left side of the heart, such as atrial fibrillation ablation, left atrial appendage closure, and mitral valve interventions. Baylis Medical Company is reportedly expected to generate net sales of roughly $200 million in 2022.

Physicians have traditionally relied on a mechanical needle to pass through the septum and access the left side of the heart, which reportedly can present safety concerns and placement challenges based on varying patient anatomy. Rather than relying solely on mechanical force, the Baylis Medical Company platforms facilitate access by using RF energy. The new VersaCross platform further streamlines transseptal crossing procedures and developers say may help mitigate risks during procedures.